Cantor Fitzgerald Begins Coverage on GALAPAGOS NV/S (GLPG)

Share on StockTwits

Stock analysts at Cantor Fitzgerald started coverage on shares of GALAPAGOS NV/S (NASDAQ:GLPG) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $130.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 30.00% from the stock’s current price.

Several other analysts also recently issued reports on GLPG. Zacks Investment Research raised shares of GALAPAGOS NV/S from a “hold” rating to a “buy” rating and set a $115.00 target price on the stock in a research note on Tuesday, December 11th. Credit Suisse Group upgraded shares of GALAPAGOS NV/S from a “neutral” rating to an “outperform” rating in a report on Thursday, December 13th. ValuEngine upgraded shares of GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 10th. BidaskClub cut shares of GALAPAGOS NV/S from a “hold” rating to a “sell” rating in a report on Saturday, September 8th. Finally, Raymond James initiated coverage on shares of GALAPAGOS NV/S in a report on Wednesday, November 14th. They set a “strong-buy” rating and a $157.00 price target on the stock. Three analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $119.39.

NASDAQ:GLPG traded up $2.14 during trading hours on Wednesday, hitting $100.00. 5,028 shares of the stock traded hands, compared to its average volume of 82,303. GALAPAGOS NV/S has a fifty-two week low of $87.36 and a fifty-two week high of $122.28. The company has a market cap of $5.21 billion, a P/E ratio of -37.86 and a beta of 1.89.

GALAPAGOS NV/S (NASDAQ:GLPG) last announced its earnings results on Friday, October 26th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.70. GALAPAGOS NV/S had a negative net margin of 30.65% and a negative return on equity of 7.66%. The company had revenue of $119.99 million for the quarter, compared to the consensus estimate of $82.15 million. Analysts expect that GALAPAGOS NV/S will post -1.72 EPS for the current year.

Several institutional investors have recently bought and sold shares of GLPG. Federated Investors Inc. PA grew its holdings in shares of GALAPAGOS NV/S by 17.8% during the 3rd quarter. Federated Investors Inc. PA now owns 1,677,922 shares of the biotechnology company’s stock valued at $188,648,000 after acquiring an additional 253,159 shares in the last quarter. Laurion Capital Management LP purchased a new position in shares of GALAPAGOS NV/S during the 3rd quarter valued at $19,841,000. Marshall Wace LLP purchased a new position in shares of GALAPAGOS NV/S during the 3rd quarter valued at $15,319,000. Jane Street Group LLC grew its holdings in shares of GALAPAGOS NV/S by 214.1% during the 3rd quarter. Jane Street Group LLC now owns 185,269 shares of the biotechnology company’s stock valued at $20,830,000 after acquiring an additional 126,277 shares in the last quarter. Finally, Aquilo Capital Management LLC purchased a new position in shares of GALAPAGOS NV/S during the 2nd quarter valued at $6,088,000. Institutional investors and hedge funds own 18.13% of the company’s stock.

About GALAPAGOS NV/S

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Featured Article: Cost of Equity

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply